These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 36269184)

  • 21. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
    Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y
    Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial.
    Wang W; Zhang F; Yu S; Ma N; Huang C; Wang M; Wei L; Zhang J; Fu A
    Eur J Pediatr; 2023 Jun; 182(6):2597-2606. PubMed ID: 36944782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Changes in Retinal Vascular Density and Thickness After Using Low-Level Red Light and 0.01% Atropine in Premyopic Children.
    Shang L; Gao S; Wang W; Chang M; Ma N; Huang C; Yu S; Wang M; Fu A
    Transl Vis Sci Technol; 2024 Jun; 13(6):23. PubMed ID: 38940757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.
    Yam JC; Zhang XJ; Zhang Y; Yip BHK; Tang F; Wong ES; Bui CHT; Kam KW; Ng MPH; Ko ST; Yip WWK; Young AL; Tham CC; Chen LJ; Pang CP
    JAMA; 2023 Feb; 329(6):472-481. PubMed ID: 36786791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population.
    Loughman J; Kobia-Acquah E; Lingham G; Butler J; Loskutova E; Mackey DA; Lee SSY; Flitcroft DI
    Acta Ophthalmol; 2024 May; 102(3):e245-e256. PubMed ID: 37694816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Low-Concentration Atropine Eye Drops in Controlling the Progression of Myopia in Children: A One- and Two-Year Follow-Up Study.
    Zhang H; Yang P; Li Y; Zhang W; Li S
    Ophthalmic Epidemiol; 2024 Jun; 31(3):240-248. PubMed ID: 37528608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial.
    Sharma I; Das GK; Rohatgi J; Sahu PK; Chhabra P; Bhatia R
    Curr Eye Res; 2023 Apr; 48(4):402-407. PubMed ID: 36576170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
    Li FF; Kam KW; Zhang Y; Tang SM; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC
    Ophthalmology; 2020 Dec; 127(12):1603-1611. PubMed ID: 32525048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.
    Wei S; Li SM; An W; Du J; Liang X; Sun Y; Zhang D; Tian J; Wang N
    JAMA Ophthalmol; 2020 Nov; 138(11):1178-1184. PubMed ID: 33001210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia.
    Zhou H; Zhao G; Li Y
    Clin Exp Optom; 2022 Jul; 105(5):520-526. PubMed ID: 34228946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of combination therapy of repeated low-level red light and defocus-incorporated multiple segments spectacle lenses for myopia control in children: the study protocol for a 12-month, randomized, parallel-controlled, and single-center clinical trial.
    Zhang H; Song D; Wei R
    Trials; 2024 Jul; 25(1):514. PubMed ID: 39080704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report.
    Zhang XJ; Zhang Y; Yip BHK; Kam KW; Tang F; Ling X; Ng MPH; Young AL; Wu PC; Tham CC; Chen LJ; Pang CP; Yam JC
    Ophthalmology; 2024 Sep; 131(9):1011-1020. PubMed ID: 38494130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial.
    Wei S; Li SM; An W; Du J; Liang X; Sun Y; Gan J; Bai W; Tian J; Cai Z; Yin L; Wang N
    Acta Ophthalmol; 2023 Mar; 101(2):e177-e184. PubMed ID: 35999653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops.
    Moriche-Carretero M; Revilla-Amores R; Diaz-Valle D; Morales-Fernández L; Gomez-de-Liaño R
    J Fr Ophtalmol; 2021 Dec; 44(10):1499-1504. PubMed ID: 34774348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of repeated low-level red light in myopia prevention and myopia control.
    Liu G; Rong H; Liu Y; Wang B; Du B; Song D; Wei R
    Br J Ophthalmol; 2024 Aug; 108(9):1299-1305. PubMed ID: 38631861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study.
    Saxena R; Gupta V; Dhiman R; Joseph E; Agarkar S; Neena R; Magdalene D; Jethani J; Ganesh SC; Patil M; Gogri P; Gadaginamath S; Sen P; Sukhija J; Mishra D; Matalia JH; Sahu A; Kapoor S; Nishanth S; Chaurasia S; Pawar N; Deori N; Sivaraman V; Bordoloi A; Tibrewal S; Singh D; Prasad P; Phuljhele S; Sharma N
    Br J Ophthalmol; 2024 Mar; 108(4):588-592. PubMed ID: 38290805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
    Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
    Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
    Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D
    Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial.
    Zadnik K; Schulman E; Flitcroft I; Fogt JS; Blumenfeld LC; Fong TM; Lang E; Hemmati HD; Chandler SP;
    JAMA Ophthalmol; 2023 Oct; 141(10):990-999. PubMed ID: 37261839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
    Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
    Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.